Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
This milestone underscores Lupin¡¦s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets.
Key short-term targets:
„h - Reduce absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by FY 2030, with FY 2023 as the base year.
„h - Reduce Scope 3 greenhouse gas emissions by 61.07% by FY 2033, across purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises, using FY 2024 as the baseline.
These goals are aligned with the 1.5¢XC pathway and validated under SBTi¡¦s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change.
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin, today announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide) (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients. This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations.
As part of the alliance, both companies will work towards the following: „h
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets, while enhancing PolyPeptide¡¦s position as a trusted CDMO partner.
Realty shares jumped for the two consecutive trading sessions.
At 10:25 IST, the barometer index, the S&P BSE Sensex, advanced 176.76 points or 0.21% to 85,442.08. The Nifty 50 index jumped 55.45 points or 0.21% to 26,089.20.
In the broader market, the S&P BSE Mid-Cap index rose 0.06% and the S&P BSE Small-Cap index added 0.54%.
The market breadth was negative. On the BSE, 1,558 shares rose and 2,014 shares fell. A total of 211 shares were unchanged.
Economy:
The Reserve Bank of India Governor Sanjay Malhotra, announcing the fifth bi-monthly policy review of FY26 said that RBI’s MPC has unanimously decided to reduce the policy repo rate by 25 basis points to 5.25%, keeping its stance neutral.
Buzzing Index:
The Nifty Realty index jumped 1.18% to 900.60. The index rose 1.72% in the two consecutive trading sessions.
Prestige Estates Projects (up 0.87%), Oberoi Realty (up 0.57%), DLF (up 0.56%), Brigade Enterprises (up 0.49%) advanced.
Stocks in Spotlight;
Kesoram Industries surged 19.85% after Frontier Warehousing announced an open offer to acquire 8.07 crore shares, representing a 26% stake, at Rs 5.48 per share.
Lupin shed 0.05%. The company announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Siponimod Tablets in 0.25 mg, 1 mg and 2 mg.
ZEN Technologies advanced 1.68% after the company announced that it has secured orders worth Rs 120 crore from the Ministry of Defence (MoD), Government of India.
Lupin said the tablets will be manufactured at its Pithampur facility in India. According to IQVIA MAT October 2025 data, Siponimod Tablets (reference listed drug Mayzent) recorded annual U.S. sales of USD 195 million.
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Lupin reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025.
The counter shed 0.21% to Rs 2,087.55 on the BSE.
Siponimod Tablets, 0.25 mg, 1 mg and 2 mg are bioequivalent to Mayzent® Tablets, 0.25 mg, 1 mg and 2 mg of Novartis Pharmaceuticals Corporation, and indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.
Siponimod Tablets (RLD Mayzent®) had estimated annual sales of USD 195 million in the U.S. (IQVIA MAT October 2025).
Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg™ (pegfilgrastim-unne) in the United States. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales.
Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
Armlupeg (pegfilgrastim-unne) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy.
“We are pleased to collaborate with Valorum to expand access to affordable treatment options for patients undergoing chemotherapy. This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the U.S. biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines,” said Spiro Gavaris, President – U.S. Generics, Lupin.
Par S. Hyare, CEO of Valorum, said, “We are excited to launch Armlupeg (pegfilgrastim-unne) in the U.S. Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise. Crucially, we also look forward to providing another option for healthcare providers and patients, increasing access to this important treatment in oncology supportive care.”
Valorum Biologics specializes in the U.S. commercialization of biosimilars, managing regulatory approval, product launch, and ongoing commercialization. The company focuses on optimizing patient access and delivering cost savings to the healthcare system.
The counter rose 0.47% to Rs 2,090.45 on the BSE.
The product will be manufactured at Lupin's Biotech facility in Pune, which was inspected by the U.S. FDA prior to approval.
Armlupeg™ is indicated for:
- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation.
Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of global pharma major Lupin, has been awarded the CRISIL Voluntary Organisation grading of VO 1A, the highest classification, indicating ‘Very Strong Delivery Capability and High Financial Proficiency.'
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility. For over 37 years, LHWRF has spearheaded initiatives to improve lives and livelihoods and strengthen healthcare for underserved populations across India. The Foundation remains dedicated to empowering communities and promoting holistic development.
“We are honored to receive the VO 1A rating from CRISIL, reflecting our commitment to social welfare and sustainable growth,” said Tushara Shankar, Head – CSR, Lupin. “This recognition inspires us to expand our innovative programs that support communities and create lasting positive impact.”
The CRISIL VO grading is a comprehensive assessment framework that evaluates an organization's overall ability to deliver on its goals. It focuses on factors such as stakeholder engagement, system and process efficiency, implementation and monitoring mechanisms, and financial management skills, including revenue and expenditure control, resource diversification, liquidity, and transparency reporting.
In the week ended on Friday, 28 November 2025, the S&P BSE Sensex advanced 474.75 points or 0.56% to settle at 85,706.67. The Nifty 50 index added 134.80 points or 0.52% to settle at 26,202.95. The BSE Mid-Cap index jumped 1.19% to close at 47,211.40. The BSE Small-Cap added 0.08% to end at 52,053.71.
Weekly Index Movement:
The domestic equity benchmarks slipped for a second straight session on Monday as profit booking and caution ahead of the US Fed’s December policy outlook kept sentiment muted. The S&P BSE Sensex tumbled 331.21 points or 0.39% to 84,900.71. The Nifty 50 index fell 108.65 points or 0.42% to 25,959.50. In two consecutive trading sessions, the Sensex fell 0.85% while the Nifty lost 0.89%.
The domestic market slipped for a third consecutive session on Tuesday, closing with moderate losses after a volatile day shaped by monthly derivatives expiry. A softer rupee and persistent FII selling kept investors on edge, while traders stayed cautious ahead of the upcoming FOMC meeting and uncertainty surrounding the interim US-India trade agreement. The S&P BSE Sensex, tumbled 313.70 points or 0.37% to 84,587.01. The Nifty 50 index fell 74.70 points or 0.29% to 25,884.80. In three consecutive trading sessions, the Sensex dropped 1.22% while the Nifty fell 1.17%.
The domestic equity benchmarks ended with robust gains on Wednesday, snapping a three-day losing streak. Sentiment improved as hopes of a US Federal Reserve rate cut strengthened. The S&P BSE Sensex surged 1,022.50 points or 1.21% to 85,609.51. The Nifty 50 index jumped 320.50 points or 1.24% to 26,205.30. In the past three consecutive trading sessions, the Sensex dropped 1.22% while the Nifty fell 1.17%.
The key equity indices ended with modest gains on Thursday, extending their advance for a second straight session. The Sensex and Nifty touched fresh record highs during the day before easing off toward the close. The S&P BSE Sensex jumped 110.87 points or 0.13% to 85,720.38. The Nifty 50 index rose 10.25 points or 0.04% to 26,215.55.
The Nifty 50 and the Sensex hit fresh all-time highs in morning trade at 26,310.45 and 86,055.86, respectively, while the Bank Nifty also scaled a new record high of 59,866.60.
The key equity barometers ended with small cuts on Friday, snapping a two-day winning run, as profit booking at higher levels and caution ahead of the Q2 GDP data release dampened sentiment, while mixed global cues provided limited support. The barometer index, the S&P BSE Sensex, declined 13.71 points or 0.02% to 85,706.67. The Nifty 50 index lost 12.60 points or 0.05% to 26,202.95.
The International Monetary Fund (IMF) said India’s economy is expected to grow 6.6% in 2025-26, noting that strong GST reforms should help soften the impact of recent US tariff hikes. It highlighted that growth remained solid, with real GDP rising 7.8% in the first quarter after expanding 6.5% in 2024-25. The Fund added that India’s goal of becoming an advanced economy will depend on pushing forward broader structural reforms to lift long-term growth potential.
Stocks in Spotlight:
Lemon Tree Hotels jumped 2.99%. The company announced the signing of its latest property, Keys Select by Lemon Tree Hotels, Bhopal, Madhya Pradesh, aimed at catering to both business and leisure travelers.
Lupin added 2.6%. The pharma major said the U.S. Food and Drug Administration (FDA) conducted an inspection at its Goa manufacturing facility from 10 November to 21 November 2025.
HCL Technologies rose 0.98%. The company announced the expansion of its collaboration with SAP to advance physical AI solutions that integrate intelligence into real-world operations across industries.
Refex Industries rallied 6.61% after the company received an order from Large Business Conglomerate for excavation, loading and transportation of pond ash/bottom ash. The said order is valued at Rs 100 crore and is expected to be completed within 4 months.
Glenmark Pharmaceuticals rallied 5.63%. The U.S. FDA issued a positive establishment inspection report (EIR) with voluntary action indicated (VAI) status for its formulations manufacturing facility in Monroe, North Carolina.
Paras Defence and Space Technologies shed 0.26%. The company signed a licensing agreement for transfer of technology with the Defence Research & Development Organisation (DRDO), under the Ministry of Defence, Government of India.
Global Market:
Headline inflation in Japan’s capital eased to 2.7% in October from 2.8% the month before. Core inflation, which strips out prices of fresh food but includes energy prices, came in at 2.8%, slightly higher than the widely reported 2.7% figure. This was above the central bank’s 2% target, boosting the case for a near-term rate hike.
The Bank of Korea kept its benchmark interest rate unchanged at 2.5% for a fourth consecutive policy meeting, amid a weakened local currency and overheated housing market.
China’s industrial profits in October plunged 5.5% from a year earlier, government data showed Thursday. Profits for the first 10 months of the year rose 1.9% year-on-year, compared to the 3.2% rise in the January-to-September period.
In Australia, the consumer price index rose 3.8% year-on-year in October, the fastest pace since adopting a new headline inflation measure in April, according to the official release. The largest contributor to the elevated inflation was the housing sector, which saw prices rise 5.9%.
In the US, the September wholesale inflation rose by 0.3%, keeping the annual level at 2.7%, according to the Bureau of Labor Statistics. Retail sales rose 0.2% in September, but after factoring in the 0.3% increase in prices that month, spending was actually down 0.1%.
The core producer price index (PPI) rose just 0.1% in September, which brought the annual rate to 2.6%, the lowest since July 2024. The consumer confidence declined sharply in November to a reading of 88.7, the lowest level since April.